Stock Expert AI

DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases. Their lead drug candidate, DM199, targets chronic kidney disease and acute ischemic stroke.

54/100 AI Score MCap 445M Vol 337K

Company Overview

CEODietrich John Pauls
Employees27
HeadquartersMinneapolis, MN, US
Founded2012

DiaMedica Therapeutics (DMAC) offers a compelling investment in innovative therapies for neurological and kidney diseases, spearheaded by DM199, a promising treatment targeting multi-billion dollar markets in chronic kidney disease and acute ischemic stroke, positioning it for significant growth.

Investment Thesis

DiaMedica Therapeutics presents a compelling investment opportunity based on the potential of DM199 to address significant unmet needs in chronic kidney disease and acute ischemic stroke. The ongoing Phase 2 REDUX trial and Phase 2/3 REMEDY2 trials represent near-term catalysts that could drive substantial value appreciation. Positive clinical data from these trials would validate the efficacy of DM199 and pave the way for potential regulatory approval and commercialization. With a market capitalization of $0.42 billion and a beta of 1.08, DMAC offers a high-risk, high-reward investment profile. Successful development and commercialization of DM199 could generate significant returns for investors, driven by the large market size and limited treatment options currently available. The company's focus on innovative therapies and experienced management team further strengthens the investment case.

Key Highlights

  • DM199 is in Phase 2 REDUX trial for chronic kidney disease, targeting a large patient population with limited treatment options.
  • DM199 is in Phase 2/3 REMEDY2 trials for acute ischemic stroke, a critical unmet medical need.
  • The company is developing DM300, a pre-clinical asset targeting inflammatory diseases, expanding its pipeline.
  • Market capitalization of $0.42 billion indicates growth potential if clinical trials are successful.
  • The company has 27 employees, reflecting a focused and efficient operational structure.

Competitors

Altimmune, Inc.Annexon, Inc.DBV Technologies S.A.Diracta Biosciences, Inc.Design Therapeutics, Inc.

Strengths

  • Promising lead drug candidate (DM199) in Phase 2 and Phase 2/3 trials.
  • Focus on areas with high unmet medical needs (CKD and AIS).
  • Proprietary technology platform for developing protein therapeutics.
  • Experienced management team.

Weaknesses

  • Clinical-stage company with no currently approved products.
  • Reliance on the success of DM199.
  • Limited financial resources.
  • Small number of employees.

Catalysts

  • Upcoming: Results from the Phase 2 REDUX trial for chronic kidney disease are expected within the next 12-18 months.
  • Upcoming: Results from the Phase 2/3 REMEDY2 trials for acute ischemic stroke are anticipated within the next 24-36 months.
  • Ongoing: Continued enrollment and progress in the Phase 2 REDUX and Phase 2/3 REMEDY2 trials.
  • Ongoing: Development and advancement of DM300 for inflammatory diseases.
  • Ongoing: Potential strategic partnerships with larger pharmaceutical companies.

Risks

  • Potential: Failure of DM199 in clinical trials could significantly impact the company's value.
  • Potential: Regulatory hurdles and delays in obtaining FDA approval.
  • Potential: Competition from other companies developing treatments for CKD and AIS.
  • Ongoing: Limited financial resources may constrain the company's ability to fund its research and development programs.
  • Ongoing: Dependence on key personnel and the ability to attract and retain qualified employees.

Growth Opportunities

  • Successful completion of the Phase 2 REDUX trial for chronic kidney disease represents a significant growth opportunity. The CKD market is estimated to be worth billions of dollars, and DM199 has the potential to capture a significant share if it demonstrates superior efficacy and safety compared to existing treatments. The timeline for completion of the trial is expected within the next 12-18 months, and positive results would be a major catalyst for the company's stock price.
  • Advancement of DM199 through the Phase 2/3 REMEDY2 trials for acute ischemic stroke offers another substantial growth avenue. AIS is a leading cause of disability and death, and there is a critical need for new and effective therapies. If DM199 proves to be successful in reducing the severity of stroke and improving patient outcomes, it could become a standard of care and generate significant revenue for DiaMedica. The results of the REMEDY2 trials are anticipated within the next 24-36 months.
  • The development of DM300 for inflammatory diseases provides a longer-term growth opportunity for DiaMedica. The inflammatory disease market is vast and diverse, encompassing conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. DM300 has the potential to address a broad range of inflammatory conditions and generate significant revenue for the company. The timeline for development of DM300 is expected to be several years, as it is currently in the pre-clinical stage.
  • Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of DM199 and DM300. Partnering with a larger company would provide DiaMedica with access to additional resources, expertise, and distribution channels. This could significantly reduce the company's financial risk and increase its chances of success. DiaMedica is actively seeking potential partners and is open to exploring various collaboration opportunities.
  • Expansion into new therapeutic areas represents a long-term growth opportunity for DiaMedica. The company could leverage its expertise in protein therapeutics to develop treatments for other neurological and kidney diseases, as well as other therapeutic areas. This would diversify the company's pipeline and reduce its reliance on DM199. DiaMedica is actively evaluating potential new therapeutic areas and is committed to expanding its pipeline through internal research and development and strategic acquisitions.

Opportunities

  • Positive clinical trial results for DM199.
  • Strategic partnerships with larger pharmaceutical companies.
  • Expansion into new therapeutic areas.
  • Increasing prevalence of CKD and AIS.

Threats

  • Failure of clinical trials.
  • Regulatory hurdles.
  • Competition from other biotechnology and pharmaceutical companies.
  • Patent challenges.

Competitive Advantages

  • Proprietary technology platform for developing protein therapeutics.
  • Strong intellectual property protection for its drug candidates.
  • Experienced management team with a proven track record of success.
  • First-mover advantage in developing rhKLK1-based therapies for CKD and AIS.

About

DiaMedica Therapeutics Inc., founded in 2000 and headquartered in Minneapolis, Minnesota, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel treatments for neurological and kidney diseases. The company's primary focus is on DM199, a recombinant human tissue kallikrein-1 (rhKLK1) protein. DM199 is currently undergoing Phase 2 REDUX trials for patients with moderate to severe chronic kidney disease (CKD) caused by Type I or Type II diabetes. Additionally, DM199 is in Phase 2/3 REMEDY2 trials for the treatment of acute ischemic stroke (AIS). These trials represent significant milestones in addressing critical unmet medical needs in these therapeutic areas. DiaMedica is also advancing DM300, a pre-clinical asset targeting inflammatory diseases, showcasing the company's commitment to expanding its pipeline and addressing a broader range of medical conditions. Formerly known as DiaMedica Inc., the company rebranded as DiaMedica Therapeutics Inc. in December 2016, reflecting its sharpened focus on therapeutic development. With a team of 27 employees, DiaMedica is striving to transform the treatment landscape for patients suffering from neurological and kidney disorders.

What They Do

  • Develops treatments for neurological diseases.
  • Develops treatments for kidney diseases.
  • Focuses on clinical-stage biopharmaceutical development.
  • Conducts Phase 2 trials for chronic kidney disease (CKD).
  • Conducts Phase 2/3 trials for acute ischemic stroke (AIS).
  • Develops DM199, a recombinant human tissue kallikrein-1 protein.
  • Advances DM300, a pre-clinical asset for inflammatory diseases.

Business Model

  • Develops and patents novel therapeutic candidates.
  • Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
  • Seeks regulatory approval from the FDA and other regulatory agencies.
  • Commercializes its approved products through its own sales force or through partnerships.

FAQ

What does DiaMedica Therapeutics Inc. do?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases. Their lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein currently in Phase 2 trials for chronic kidney disease and Phase 2/3 trials for acute ischemic stroke. The company aims to address unmet medical needs in these areas by developing innovative therapies that improve patient outcomes. DiaMedica is also developing DM300, a pre-clinical asset targeting inflammatory diseases, demonstrating a commitment to expanding its pipeline and addressing a broader range of medical conditions.

Is DMAC stock a good buy?

DMAC stock represents a high-risk, high-reward investment opportunity. The potential for significant returns is tied to the success of DM199 in clinical trials. Positive results from the ongoing Phase 2 REDUX and Phase 2/3 REMEDY2 trials could drive substantial value appreciation. However, the company's limited financial resources and reliance on DM199 also pose significant risks. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in DMAC. With a market cap of $0.42 billion, successful trials could lead to substantial gains, but failure could result in significant losses.

What are the main risks for DMAC?

The main risks for DMAC include the potential failure of DM199 in clinical trials, which would significantly impact the company's value. Regulatory hurdles and delays in obtaining FDA approval also pose a risk. Competition from other companies developing treatments for CKD and AIS could limit DM199's market potential. Additionally, the company's limited financial resources may constrain its ability to fund its research and development programs. Dependence on key personnel and the ability to attract and retain qualified employees are also important considerations. These factors contribute to the high-risk nature of investing in DMAC.

What is DM199 and how does it work?

DM199 is DiaMedica Therapeutics' lead drug candidate, a recombinant human tissue kallikrein-1 (rhKLK1) protein. It is designed to treat neurological and kidney diseases by supplementing the body's natural KLK1, an enzyme that plays a crucial role in regulating blood flow, inflammation, and oxidative stress. In chronic kidney disease, DM199 aims to improve kidney function by enhancing blood flow and reducing inflammation. In acute ischemic stroke, DM199 seeks to protect brain tissue from damage by improving blood supply and reducing inflammation. The drug is administered intravenously and is currently being evaluated in Phase 2 and Phase 2/3 clinical trials.

What is the significance of the REMEDY2 and REDUX trials?

The REMEDY2 and REDUX trials are critical milestones for DiaMedica Therapeutics. REMEDY2 is a Phase 2/3 trial evaluating DM199 for the treatment of acute ischemic stroke. Positive results from this trial could lead to regulatory approval and commercialization of DM199 for this indication. REDUX is a Phase 2 trial assessing DM199 for the treatment of chronic kidney disease. Success in this trial would validate DM199's potential to improve kidney function and slow the progression of CKD. Both trials represent significant opportunities for DiaMedica to address unmet medical needs and generate value for its shareholders. The outcomes of these trials will be pivotal in determining the future of the company.

Industry Context

DiaMedica Therapeutics operates within the biotechnology industry, which is characterized by high innovation, significant regulatory hurdles, and substantial market opportunities. The company focuses on neurological and kidney diseases, areas with growing prevalence and unmet medical needs. The market for chronic kidney disease and acute ischemic stroke treatments is substantial, driven by aging populations and increasing incidence of these conditions. DiaMedica competes with other biotechnology and pharmaceutical companies developing therapies for these indications. Competitors include ALT, ANNX, DBVT, DRTS, and DSGN. The success of DiaMedica depends on the clinical efficacy and safety of its drug candidates, as well as its ability to navigate the regulatory approval process and secure market access.

Key Customers

  • Patients suffering from chronic kidney disease (CKD).
  • Patients suffering from acute ischemic stroke (AIS).
  • Healthcare providers who treat patients with CKD and AIS.
  • Hospitals and clinics that provide care for patients with CKD and AIS.
AI Confidence: 82% Updated: 2/9/2026

Financials

Chart & Info

Price Chart

DiaMedica Therapeutics Inc. (DMAC) stock price: $8.54 (+0.61, +7.69%)

Why Bull

  • •Recent insider buying suggests confidence in DiaMedica's pipeline, echoing similar signals seen before positive trial results in other biotechs.
  • •Community sentiment shows increasing optimism about DiaMedica's potential in treating unmet medical needs, mirroring the early enthusiasm for novel therapies.
  • •Bullish views highlight the potential for DMAC's lead drug candidate to disrupt the market, similar to how Vertex's cystic fibrosis drugs changed their treatment landscape.
  • •Market perception is improving as DMAC gains attention for its innovative approach, reminiscent of the early days of CRISPR companies.

Why Bear

  • •Some insiders may be selling shares for personal financial reasons, which doesn't always reflect negatively on the company's prospects, but warrants caution.
  • •Community concerns exist regarding the timeline for clinical trials and potential regulatory hurdles, similar to challenges faced by other small-cap biopharma companies.
  • •Bearish views emphasize the risk of clinical trial failures, a common concern in the biotech sector, akin to the setbacks experienced by many gene therapy companies.
  • •Market perception is still cautious due to the inherent risks associated with drug development, reflecting the skepticism often directed at companies with limited approved products.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
336,686

Rationale

AI-generated technical analysis for DMAC including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss DiaMedica Therapeutics Inc. (DMAC) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for DMAC.

Make a Prediction

Set your price target for DiaMedica Therapeutics Inc. (DMAC), choose a timeframe, and track your prediction accuracy.

Current price: $8.54

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMAC.

Price Targets

Wall Street price target analysis for DMAC.

Insider Flow (30d)

Semba Charles Pauling
Insider
1 month ago
BOUGHT
47,963 shares
$404K
Parsons James T.
Insider
1 month ago
BOUGHT
97,949 shares
$825K
Giuffre Randall Michael
Insider
1 month ago
BOUGHT
398,587 shares
$3.4M
TRILL AB
Insider
2 months ago
BOUGHT
8,825,742 shares
$75.7M
TRILL AB
Insider
3 months ago
BOUGHT
8,752,643 shares
$69.1M

MoonshotScore

54/100

Score Factors

  • Revenue Growth 5/100
  • Gross Margin 5/100
  • Operating Leverage 4/100
  • Cash Runway 5/100
  • R&D Intensity 5/100
  • Insider Activity 6/100
  • Short Interest 10/100
  • Price Momentum 6/100
  • News Sentiment 5/100

What does this score mean?

The MoonshotScore rates DMAC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Healthcare/Biotechnology

Competitors & Peers

Latest News

Frequently Asked Questions

What does DiaMedica Therapeutics Inc. do?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases. Their lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein currently in Phase 2 trials for chronic kidney disease and Phase 2/3 trials for acute ischemic stroke. The company aims to address unmet medical needs in these areas by developing innovative therapies that improve patient outcomes. DiaMedica is also developing DM300, a pre-clinical asset targeting inflammatory diseases, demonstrating a commitment to expanding its pipeline and addressing a broader range of medical conditions.

Is DMAC stock a good buy?

DMAC stock represents a high-risk, high-reward investment opportunity. The potential for significant returns is tied to the success of DM199 in clinical trials. Positive results from the ongoing Phase 2 REDUX and Phase 2/3 REMEDY2 trials could drive substantial value appreciation. However, the company's limited financial resources and reliance on DM199 also pose significant risks. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in DMAC. With a market cap of $0.42 billion, successful trials could lead to substantial gains, but failure could result in significant losses.

What are the main risks for DMAC?

The main risks for DMAC include the potential failure of DM199 in clinical trials, which would significantly impact the company's value. Regulatory hurdles and delays in obtaining FDA approval also pose a risk. Competition from other companies developing treatments for CKD and AIS could limit DM199's market potential. Additionally, the company's limited financial resources may constrain its ability to fund its research and development programs. Dependence on key personnel and the ability to attract and retain qualified employees are also important considerations. These factors contribute to the high-risk nature of investing in DMAC.

What is DM199 and how does it work?

DM199 is DiaMedica Therapeutics' lead drug candidate, a recombinant human tissue kallikrein-1 (rhKLK1) protein. It is designed to treat neurological and kidney diseases by supplementing the body's natural KLK1, an enzyme that plays a crucial role in regulating blood flow, inflammation, and oxidative stress. In chronic kidney disease, DM199 aims to improve kidney function by enhancing blood flow and reducing inflammation. In acute ischemic stroke, DM199 seeks to protect brain tissue from damage by improving blood supply and reducing inflammation. The drug is administered intravenously and is currently being evaluated in Phase 2 and Phase 2/3 clinical trials.

What is the significance of the REMEDY2 and REDUX trials?

The REMEDY2 and REDUX trials are critical milestones for DiaMedica Therapeutics. REMEDY2 is a Phase 2/3 trial evaluating DM199 for the treatment of acute ischemic stroke. Positive results from this trial could lead to regulatory approval and commercialization of DM199 for this indication. REDUX is a Phase 2 trial assessing DM199 for the treatment of chronic kidney disease. Success in this trial would validate DM199's potential to improve kidney function and slow the progression of CKD. Both trials represent significant opportunities for DiaMedica to address unmet medical needs and generate value for its shareholders. The outcomes of these trials will be pivotal in determining the future of the company.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.